IBRX
Price
$3.43
Change
+$0.03 (+0.88%)
Updated
Oct 4 closing price
41 days until earnings call
JAGX
Price
$1.28
Change
-$0.03 (-2.29%)
Updated
Oct 4 closing price
Ad is loading...

IBRX vs JAGX

Header iconIBRX vs JAGX Comparison
Open Charts IBRX vs JAGXBanner chart's image
ImmunityBio
Price$3.43
Change+$0.03 (+0.88%)
Volume$1.55M
CapitalizationN/A
Jaguar Health
Price$1.28
Change-$0.03 (-2.29%)
Volume$243.13K
CapitalizationN/A
View a ticker or compare two or three
IBRX vs JAGX Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
IBRX vs. JAGX commentary
Oct 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a StrongSell and JAGX is a Buy.

COMPARISON
Comparison
Oct 06, 2024
Stock price -- (IBRX: $3.44 vs. JAGX: $1.28)
Brand notoriety: IBRX and JAGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 47% vs. JAGX: 64%
Market capitalization -- IBRX: $2.58B vs. JAGX: $12.57M
IBRX [@Biotechnology] is valued at $2.58B. JAGX’s [@Biotechnology] market capitalization is $12.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 0 FA rating(s) are green whileJAGX’s FA Score has 1 green FA rating(s).

  • IBRX’s FA Score: 0 green, 5 red.
  • JAGX’s FA Score: 1 green, 4 red.
According to our system of comparison, JAGX is a better buy in the long-term than IBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 4 TA indicator(s) are bullish while JAGX’s TA Score has 4 bullish TA indicator(s).

  • IBRX’s TA Score: 4 bullish, 5 bearish.
  • JAGX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both IBRX and JAGX are a bad buy in the short-term.

Price Growth

IBRX (@Biotechnology) experienced а -12.47% price change this week, while JAGX (@Biotechnology) price change was +6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

IBRX is expected to report earnings on Nov 15, 2024.

JAGX is expected to report earnings on May 19, 2023.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.58B) has a higher market cap than JAGX($12.6M). IBRX YTD gains are higher at: -31.474 vs. JAGX (-85.909). JAGX has higher annual earnings (EBITDA): -30.6M vs. IBRX (-436.05M). IBRX has more cash in the bank: 218M vs. JAGX (16M). JAGX has less debt than IBRX: JAGX (34.2M) vs IBRX (736M). JAGX has higher revenues than IBRX: JAGX (10.2M) vs IBRX (1.31M).
IBRXJAGXIBRX / JAGX
Capitalization2.58B12.6M20,508%
EBITDA-436.05M-30.6M1,425%
Gain YTD-31.474-85.90937%
P/E RatioN/A0.28-
Revenue1.31M10.2M13%
Total Cash218M16M1,363%
Total Debt736M34.2M2,152%
FUNDAMENTALS RATINGS
IBRX vs JAGX: Fundamental Ratings
IBRX
JAGX
OUTLOOK RATING
1..100
129
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6165
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (18) in the Pharmaceuticals Generic industry is somewhat better than the same rating for IBRX (77) in the Biotechnology industry. This means that JAGX’s stock grew somewhat faster than IBRX’s over the last 12 months.

IBRX's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

IBRX's SMR Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

IBRX's Price Growth Rating (61) in the Biotechnology industry is in the same range as JAGX (65) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

JAGX's P/E Growth Rating (92) in the Pharmaceuticals Generic industry is in the same range as IBRX (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXJAGX
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
87%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSLRX44.070.57
+1.31%
Hartford Small Cap Growth R3
OAZWX23.590.23
+0.98%
Oakmark Global Select R6
NDVRX17.470.16
+0.92%
MFS New Discovery Value R1
RSLEX69.390.52
+0.76%
American Funds SMALLCAP World R4
NABEX12.29N/A
N/A
Neuberger Berman Abs Ret Multi-Mgr E

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
+1.18%
AXON - IBRX
48%
Loosely correlated
+1.63%
ARRY - IBRX
41%
Loosely correlated
+2.06%
DAWN - IBRX
39%
Loosely correlated
+2.17%
AMRN - IBRX
37%
Loosely correlated
+2.14%
NTLA - IBRX
37%
Loosely correlated
+1.93%
More

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-2.29%
HEPA - JAGX
29%
Poorly correlated
+1.77%
VXRT - JAGX
28%
Poorly correlated
-1.07%
AFMD - JAGX
26%
Poorly correlated
-1.23%
SNPX - JAGX
26%
Poorly correlated
-0.34%
SLNO - JAGX
26%
Poorly correlated
+1.39%
More